• Please log in or register to access this feature.

Early Detection and Diagnosis

You have full text access to this OnlineOpen article

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

  1. Jack Cuzick1,†,*,
  2. Christine Clavel2,
  3. Karl-Ulrich Petry3,
  4. Chris J.L.M. Meijer4,
  5. Heike Hoyer5,
  6. Samuel Ratnam6,
  7. Anne Szarewski1,
  8. Philippe Birembaut2,
  9. Shalini Kulasingam7,
  10. Peter Sasieni1,
  11. Thomas Iftner8

Article first published online: 3 APR 2006

DOI: 10.1002/ijc.21955

Issue

International Journal of Cancer

International Journal of Cancer

Volume 119, Issue 5, pages 1095–1101, 1 September 2006

Additional Information

How to Cite

Cuzick, J., Clavel, C., Petry, K.-U., Meijer, C. J.L.M., Hoyer, H., Ratnam, S., Szarewski, A., Birembaut, P., Kulasingam, S., Sasieni, P. and Iftner, T. (2006), Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer, 119: 1095–1101. doi: 10.1002/ijc.21955

Author Information

  1. 1

    Cancer Research UK, Wolfson Institute of Preventive Medicine, London, United Kingdom

  2. 2

    Laboratoire Pol Bouin, C.H.U. de Reims, Reims, France

  3. 3

    Abteilung für Gynäkologische Onkologie MHH, Hannover, Germany

  4. 4

    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands

  5. 5

    Institute of Medical Statistics, Friedrich Schiller University, Jena, Germany

  6. 6

    Public Health Laboratory, Memorial University, St. John's, NL, Canada

  7. 7

    Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA

  8. 8

    Experimentelle Virologie, Universitaets-klinikum Tuebingen, Tuebingen, Germany

  1. †

    Fax: +40-20-7014-0269.

*Cancer Research UK, Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary School of Medicine, Charterhouse Square, London EC1M 6BQ, UK

  1. †

    Fax: +40-20-7014-0269.

Publication History

  1. Issue published online: 5 JUN 2006
  2. Article first published online: 3 APR 2006
  3. Manuscript Accepted: 1 FEB 2006
  4. Manuscript Received: 21 OCT 2005

Funded by

  • EC-grant. Grant Number: QLG4-CJ-2000-1238-HPVCCS

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (311K)

References

  • 1
    Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987; 1: 1247–9.
  • 2
    Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. Br J Cancer 1996; 73: 1001–5.
  • 3
    IARC. Handbooks of cancer prevention, vol. 10. cervix cancer screening. Lyon: IARC Press, 2005.
  • 4
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 1–3.
    Direct Link:
  • 5
    Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P. HPV testing in primary screening of older women. Br J Cancer 1999; 81: 554–8.
  • 6
    Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 89: 1616–23.
  • 7
    Schneider A, Hoyer H, Lotz B, Leistritza S, Kuhne-Heid R, Nindl I, Muller B, Haerting J, Durst M. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000; 89: 529–34.
    Direct Link:
  • 8
    Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000; 9: 945–51.
  • 9
    Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Evaluation of human papilomavirus testing in primary screening for cervical abnormalities. JAMA 2002; 288: 1749–57.
  • 10
    Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, van den Akker E, Iftner T. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003; 88: 1570–7.
  • 11
    Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871–6.
  • 12
    Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, v Groningen K, Boon ME, Keuning HJ, van Ballegooijen, et al. POBASCAM, a population-based randomised controlled trial for implementation of high-risk HPV testing in cervical screening. Int J Cancer 2004; 110: 94–110.
    Direct Link:
  • 13
    Venturoli S, Cricca M, Bonvicini F, Giosa F, Pulvirenti FR, Galli C, Musiani M, Zerbini M. Human papillomavirus DNA testing by PCR-ELISA and hybrid capture II from a single cytological specimen: concordance and correlation with cytological results. Clin Virol 2002; 25: 177–85.
  • 14
    Sasieni P. Estimating prevalence when the true disease status is incompletely ascertained. Stat Med 2001; 20: 935–49.
    Direct Link:
  • 15
    Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357: 1831–6.
  • 16
    Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999 354: 20–5.
  • 17
    Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325(7364): 572.
  • 18
    Elfgren K, Rylander E, Radberg T, Strander B, Strand A, Panjanen K, Sjoberg I, Ryd W, Silins I, Dillner J. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstret Gynecol 2005; 193: 650–7.
  • 19
    Wright TC,Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, Hatch K, Noller KL, Roach N, Runowicz C, Saslow D. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004; 103: 304–9.
  • 20
    Sasieni P, Cuzick J. Can HPV testing become the sole primary cervical screening test? J Med Screen 2002; 9: 49–51.
  • 21
    Kotaniemi-Talonen I, Nieminen P, Anttila A, Hakama M. Routine cervical with primary HPV testing and cytology triage protocol in a randomised setting. Brit J Cancer 2005; 93: 862–7.
View Full Article (HTML) Get PDF (311K)